Please ensure Javascript is enabled for purposes of website accessibility

Obama's Budget Bludgeons Big Pharma

By Dave Williamson and Max Macaluso - Apr 21, 2013 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The health-care stocks winning and losing in the president's proposed budget.

From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about a potentially landmark Supreme Court ruling, the impact of President Obama's budget on health-care stocks, the next wave of innovation for the pharma industry, and why investors need to pay attention to a small research company from upstate New York.

In the following segment, health-care analyst David Williamson takes a closer look at Obama's budget. There are definite winners and losers as the administration looks to protect certain parts of the sector while hitting others as Obamacare continues its rollout. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.88 (0.78%) $0.41
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.41 (0.30%) $0.20
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$302.60 (1.25%) $3.75
HCA Healthcare, Inc. Stock Quote
HCA Healthcare, Inc.
HCA
$205.04 (0.13%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.